ABBOTT ENTERS INTO CONSENT DECREED WITH U.S. FOOD AND DRUG ADMINISTRATION FOR ITS STURGIS, MICH., PLANT; AGREEMENT CREATES PATHWAY TO REOPEN FACILITY

- After FDA approval, Abbott could restart the site within two weeks; from the time of restart it would take six to eight weeks before product is available on shelves
- Abbott will continue to import formula from FDA-registered facility in Ireland to help alleviate near-term supply shortage
- CDC concluded its investigation with no findings of a link between Abbott formulas and infant illnesses

ABBOTT PARK, Ill., May 16, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) has agreed to enter into a consent decree with the U.S. Food and Drug Administration (FDA) related to its Sturgis, Mich., infant formula plant. The decree is an agreement between FDA and Abbott on the steps necessary to resume production and maintain the facility. This does not affect any other Abbott plant or operation. The decree is subject to court approval.

"Our number one priority is getting infants and families the high-quality formulas they need, and this is a major step toward re-opening our Sturgis facility so we can ease the nationwide formula shortage. We look forward to working with the FDA to quickly and safely re-open the facility," said Robert B. Ford, chairman and chief executive officer, Abbott. "We know millions of parents and caregivers depend on us and we’re deeply sorry that our voluntary recall worsened the nationwide formula shortage. We will work hard to re-earn the trust that moms, dads and caregivers have placed in our formulas for more than 50 years."

Once the FDA confirms the initial requirements for start-up have been met, Abbott could restart the site within two weeks. The company would begin production of EleCare®, Alimentum® and metabolic formulas first and then begin production of Similac® and other formulas. From the time Abbott restarts the site, it will take six to eight weeks before product is available on shelves.

Abbott has been working on corrective actions since the FDA inspection and submitted a response and corrective action plan to FDA on April 8. Even before its formal response, Abbott had begun working to implement improvements and take corrective action. Some of these actions included reviewing and updating education, training and safety procedures for both employees and visitors, as well as updating protocols regarding water, cleaning and maintenance procedures at the facility. Abbott immediately implemented corrections to address the items that the FDA raised in its observations provided at the conclusion of the inspection. The company has also been making upgrades to the plant.

**Detailed Findings of Investigation**

After a thorough investigation by FDA, Centers for Disease Control and Prevention (CDC) and Abbott, and review of all available data, there is no conclusive evidence to link Abbott’s formulas to these infant illnesses. Specifically:

- CDC concluded its investigation with no findings of a link between Abbott formulas and infant illnesses.
- Abbott conducts microbiological testing on products prior to distribution and no Abbott formula distributed to consumers tested positive for Cronobacter sakazakii or Salmonella.
- All retained product tested by Abbott and the FDA during the inspection of the facility...
came back negative for *Cronobacter sakazakii* and/or *Salmonella*. No *Salmonella* was found at the Sturgis facility.

- The *Cronobacter sakazakii* that was found in environmental testing during the investigation was in non-product contact areas of the facility and has not been linked to any known infant illness.
- Genetic sequencing on the two available samples from ill infants did not match the strains of *Cronobacter sakazakii* found in our plant. Samples from ill infants did not match each other, which means there was no connection between the two cases.
- In all four cases, the state, FDA and/or CDC tested samples of the Abbott formula that was used by the child. In all four cases, all unopened containers tested negative.
- Open containers from the homes of the infants were also tested in three of the four cases; two of the three tested negative. The one positive was from an open container from the home of the infant, and it tested positive for two different strains of *Cronobacter sakazakii*, one of which matched the strain that caused the infant's infection, and the other matched a strain found on a bottle of distilled water in the home used to mix the formula. Again, neither strain matched strains found in our plant.
- The infants consumed four different types of our formula made over the course of nearly a year and the illnesses took place over several months in three different states.

*Cronobacter sakazakii* is naturally occurring and found nearly everywhere in the environment. Powdered infant formula manufacturers periodically detect it in their plants, and FDA, in issuing its infant formula Current Good Manufacturing Practices (cGMP) regulations, stated that, based on current technologies, it is not possible to produce a sterile powdered infant formula (79 Fed. Reg. 7987). However, Abbott has no tolerance for *Cronobacter sakazakii* in its production environment, and no Abbott product was distributed with *Cronobacter sakazakii* contamination. The company is further strengthening its processes and using advanced technologies to enhance sanitization procedures, product tracking and monitoring as well as training protocols for employees and visitors.

"Our safety and quality processes meet even the toughest scrutiny and we're committed to continuously improving our processes and protocols," said Mr. Ford. "Nutrition is fundamental to Abbott and to our goal of improving the lives of more than 3 billion people by decade's end. We intend to set the standard for the industry, raising the bar on both safety and quality."

**Abbott's Efforts to Support Formula Supply Since the Recall**

Since the recall, the company has taken numerous measures to mitigate the supply shortage. Specifically, it has focused on production in its Cootehill, Ireland, facility to serve state Special Supplemental Nutrition Program for Women, Infants and Children (WIC) consumers.

Abbott has been working with the U.S. Department of Agriculture (USDA) and WIC agencies and paying rebates on competitive products in states where Abbott holds the WIC contract, when Similac is not available. Abbott said Friday it will continue to pay rebates for competitive products through August 31. This means program participants will continue to be able to obtain formula free of charge, whether it is Similac or formula from another manufacturer. Additionally, the company has:

- Air shipped millions of cans of infant formula powder into the U.S. from our FDA-registered facility in Cootehill, Ireland.
- Prioritized infant formula production at our Columbus, Ohio, facility, converting other liquid manufacturing lines into manufacturing Similac liquid ready-to-feed and ramped production at our other U.S. manufacturing site in Casa Grande, Arizona, for powder infant formula.
• Offered an increased number and value of coupons available for all infant formula products, including Similac liquid ready-to-feed, to enable customers to purchase formula, either free or deeply discounted.
• Been running other facilities at full capacity to help replenish the supply in the market.

**Abbott Guidance Unchanged**
Abbott is confirming its previously issued full-year 2022 guidance for adjusted diluted earnings per share from continuing operations of at least $4.70. Abbott will incur one-time specified charges for expenses related to the consent decree which have not yet been quantified. However, Abbott does not expect that these expenses will have a material impact on Abbott's consolidated financial statements.

**About Abbott**
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.


— Private Securities Litigation Reform Act of 1995 —
**A Caution Concerning Forward-Looking Statements**

*Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.*

**SOURCE** Abbott

For further information: Abbott Media: Jonathon Hamilton, jonathon.hamilton@abbott.com, (224) 667-8646, Vicky Assardo, vicky.assardo@abbott.com, (224) 668-1505, John Koval, john.koval@abbott.com, (224) 668-5355, Abbott Financial: Laura Dauer, laura.dauer@abbott.com, (224) 667-2299

Additional assets available online: